LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40531520PMC12177731 | 2025-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Blunted exercise hyperemic response to lower limb exercise in individuals with Down syndrome.Am J Physiol Heart Circ PhysiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40588365无 PMCID | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.Blood Cancer J | PMID 40750774PMC12317119 | 2025-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.Invest Ophthalmol Vis Sci已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40833323PMC12383881 | 2025-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.JAMA Netw Open | PMID 40833694PMC12368675 | 2025-Aug-01 | 0.95 | The record describes a secondary analysis examining the effect of statin use on outcomes in patients from two primary phase 3 randomized trials. While it references oncology, human, randomized, phase 3, and time-to-event criteria, it is not the original primary result report of a drug intervention trial and lacks a drug intervention as the primary focus, leading to ineligibility. | 已完成 |
| Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials.Cardiovasc Drugs Ther入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 38446275PMC12297002 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of ON101 for Hard-to-Heal Diabetic Foot Ulcers in a Randomized Phase III Trial: A Post Hoc Analysis.Adv Wound Care (New Rochelle)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 38780901无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.J Eur Acad Dermatol Venereol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 multi panel km;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 39101698PMC12290999 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.J Eur Acad Dermatol Venereol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 39425517PMC12291009 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term follow-up of a randomized, double-blind, phase III, multi-centre study to evaluate the safety and efficacy of field-directed photodynamic therapy (PDT) of mild to moderate actinic keratosis using BF-200 ALA versus placebo and the BF-RhodoLED® lamp.J Eur Acad Dermatol Venereol已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:森林图/亚组分析图;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。 | PMID 39666443PMC12291023 | 2025-Aug | 0.95 | The study is a Phase III randomized trial in actinic keratosis (pre-malignant) evaluating photodynamic therapy with BF-200 ALA vs placebo. While it is oncology-related and reports original results, the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS) but rather response/recurrence rates at specific time points. The study does not report Kaplan-Meier curves or hazard ratios for survival or time-to-event endpoints. | 无 KM 图 |
| CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.Allergy已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。 | PMID 39785096PMC12368742 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.Eur J Heart Fail已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。 | PMID 39956649PMC12482839 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39978598无 PMCID | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study.Clin Transl Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。 | PMID 39984775PMC12259725 | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.Clin Exp Allergy已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 39988927PMC12325141 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial.Ophthalmol RetinaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40015680无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.Allergy已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:ROC 图;FIGURE 2:AI 判定为 multi panel km;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 forest plot;FIGURE 5:AI 判定为 other。 | PMID 40028832PMC12368748 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial.Clin Lymphoma Myeloma Leuk疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40087058无 PMCID | 2025-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica.J Clin Pharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40105153无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.GastroenterologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40113101无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.Lancet Infect Dis已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other。 | PMID 40120597PMC12287245 | 2025-Aug | 0.95 | The study is a randomized, Phase 3 trial with a drug intervention and reports original results. However, the primary efficacy endpoint is immunogenicity (antibody concentrations), not a time-to-event outcome. The inclusion criteria explicitly require a primary/key secondary time-to-event efficacy endpoint, which is absent. | 无 KM 图 |
| Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities.Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40204253无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.Eur J Heart Fail | PMID 40222820PMC12482838 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema.Allergy已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 40251904PMC12368753 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.Am J Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40280279无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Custodiol-N versus Custodiol: Results from a prospective noninferiority randomized single blind, multicenter phase 3 trial in patients undergoing heart transplantation.J Heart Lung Transplant疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40280454无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.Eur J Heart Fail已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。 | PMID 40300840PMC12482849 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of SDT-001, a dual-task digital device, in managing attention-deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment-controlled study.Psychiatry Clin Neurosci已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 multi panel km;Fig. 3:AI 判定为 other。 | PMID 40317565PMC12319664 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40318950无 PMCID | 2025-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| QuantiFERON-TB supernatant-based biomarkers predicting active tuberculosis progression.Int J Infect Dis入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40320069无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials.BJOG已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram。 | PMID 40326221PMC12232536 | 2025-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40328571无 PMCID | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:AI 判定为 other;FIGURE 3:生活质量量表图。 | PMID 40365662PMC12232368 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosis.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40370077无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40383193无 PMCID | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40383194无 PMCID | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Intrafraction motion stability of open vs. closed facemasks in head and neck radiotherapy: Insights from the OPEN phase III trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40409364无 PMCID | 2025-Aug | 0.90 | While the record is from a human, randomized, phase III oncology trial, it reports only on technical/physics outcomes (intrafraction motion stability) and does not include any clinical efficacy outcomes (survival, progression, recurrence, death, hazard, time-to-event) required for inclusion in the cohort. | 无 KM 图 |
| Presentation and outcomes of second primary malignancies (SPMs) in locally advanced oral cavity squamous carcinoma (LA-OSCC): Secondary analysis of a phase III randomised control trial (NCT00193843).Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40409369无 PMCID | 2025-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study.Genet Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40411344无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort.Genet MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40411345无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.Cancer Commun (Lond) | PMID 40440184PMC12365545 | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.J Clin Oncol | PMID 40448579PMC12288889 | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.Nat Med | PMID 40450141PMC12353837 | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.Clin Obes已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。 | PMID 40452267PMC12289406 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d'un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d'innocuité et d'efficacité à court terme.Can J Psychiatry入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40452389PMC12129950 | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.J Clin OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40459178无 PMCID | 2025-Aug | 0.95 | The trial is a Phase III randomized study in oncology with drug intervention and reports original results, but its coprimary endpoints are overall response rate (ORR) and pharmacokinetic noninferiority (Ctrough), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or hazard ratio for such an endpoint is reported. | 无 KM 图 |
| Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial.Br J AnaesthPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40461346无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United States.Expert Rev Anti Infect Ther入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40478680无 PMCID | 2025-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图;FIG A1.:森林图/亚组分析图;另有 1 张未列出。 | PMID 40479620PMC12288890 | 2025-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40483179无 PMCID | 2025-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |